Loading...
•
Sep 30, 2024
Zimmer Biomet Q3 2024 Earnings Report
Reported a 4.0% increase in net sales and adjusted diluted earnings per share of $1.74.
Key Takeaways
Zimmer Biomet reported a strong third quarter with net sales of $1.824 billion, a 4.0% increase over the prior year. Diluted earnings per share were $1.23, and adjusted diluted earnings per share were $1.74. The company has updated its 2024 financial guidance, reducing and narrowing the range for the full-year outlook.
Third quarter net sales increased 4.0% to $1.824 billion, or 4.1% on a constant currency basis.
Third quarter diluted earnings per share were $1.23; adjusted diluted earnings per share were $1.74.
The company announced plans for the broad commercial launch of the Z1™ Femoral Hip System.
Zimmer Biomet completed the acquisition of OrthoGrid Systems Inc.
Zimmer Biomet
Zimmer Biomet
Zimmer Biomet Revenue by Segment
Revenue by Segment
Knees Revenue
CapyFin.comHips Revenue
CapyFin.comS.E.T. Revenue
CapyFin.comTech/Data/Surgical Revenue
CapyFin.com Forward Guidance
The Company is updating its full-year 2024 financial guidance to reduce and narrow its previous projected ranges for revenue growth and adjusted diluted EPS.
Positive Outlook
- 2024 Reported Revenue Change: 3.5% - 4.0%
- Foreign Currency Exchange Impact: (0.75)%
- 2024 Constant Currency Revenue Change: 4.25% - 4.75%
- Adjusted Diluted EPS: $7.95 - $8.05
Revenue & Expenses
Visualization of income flow from segment revenue to net income